| Methods |
2‐ to 4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 100‐115 mm Hg after run‐in; 8‐week double‐blind treatment |
| Participants |
All patients: n=454(286 males,168 females); mean age=53.8 years;
Benazepril 10 mg: n=116; baseline SBP=155.3 mm Hg, DBP=104.2 mm Hg, HR=74.2 bpm;
Placebo: n=115; baseline SBP=156.1 mm Hg, DBP=105.1 mm Hg, HR=74.4 bpm |
| Interventions |
Benazepril 10 mg once daily;
Placebo;
administered at approximately 8 AM |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
Mean change from baseline in trough sitting HR;
WDAE |
| Notes |
BP change reported, SD of change not reported; endpoint BP and SD not reported, baseline SD not reported, imputed overall trial mean SBP and DBP SD of change; BP and HR data from Table 1, p. 497; Jadad score=5; funding source= Novartis Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
